Navigation Links
UBM Medica's ONCOLOGY to Feature Special Content on Role of Genetic Testing in GI Cancers
Date:2/10/2012

NORWALK, Conn., Feb. 10, 2012 /PRNewswire/ -- UBM Medica's ONCOLOGY and CancerNetwork today announced that the April issue will feature insights by physicians from the clinical genetics service at Memorial Sloan-Kettering Cancer Center in which they explain the role of genetic testing in gastrointestinal cancers.

In the article, Kenneth Offit, MD, MPH, and colleagues bring clarity to when, why—and to what end—to refer patients for genetic testing for GI cancers. Using a case-based approach to illustrate what is known and unknown about weak and strong hereditary factors for GI cancers, the authors demonstrate how this knowledge can be used to improve outcomes in those who are predisposed to developing these malignancies.

"While there has been extraordinary attention paid by oncologists ... to inherited breast and ovarian cancer, the syndromes of predisposition to colon, gastric, and other GI cancers are of equal importance," said Dr. Offit, who is currently Chief of the Clinical Genetics Service at Memorial Sloan-Kettering. He noted that although "the genetics of hereditary colon cancer, for example, appears much more complex than breast cancer, as it involves several genes and dominant as well as recessive forms of inheritance," genetic counseling and testing for colon cancer risk has an important advantage: the availability of targeted endoscopic surveillance to remove premalignant lesions. The authors point out that "there are relatively few diseases in which early identification of at-risk individuals can have such dramatic outcomes from primary disease prevention."

The authors include Kasmintan Schrader, MD, Kenneth Offit, MD, MPH, and Zsofia K. Stadler, MD. Dr. Offit is known world-wide for his work in cancer genetics. It was his research group that in 1996 first described the common genetic mutations of the BRCA1 and BRCA2 genes that are associated with increased breast cancer risk.

About UBM Medica

Addressing today's healthcare information needs, UBM Medica, a division of UBM plc (UBM.L), delivers strategic, integrated communications solutions and comprehensive reach—online, in print, live, and via custom programs. Improving the effectiveness of healthcare through information and education, UBM Medica provides unbiased clinical, practical, and business information for physicians, providers, payers, and patients around the world. Through journals, magazines, websites, drug databases, data services, live events, and other valuable resources, UBM Medica also delivers comprehensive communication solutions for the pharmaceutical and related industries. US websites include PsychiatricTimes.com, CancerNetwork.com, DiagnosticImaging.com, ConsultantLive.com, OBGYN.net, PhysiciansPractice.com and SearchMedica.com.  Employing more than 1,400 people with offices in 29 countries, UBM Medica is headquartered in London.  For more information, visit http://www.ubmmedica.com/.

Media contact:
Amy Erdman
Director of Marketing
203-523-7041
amy.erdman@ubm.com


'/>"/>
SOURCE UBM Medica
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
3. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
4. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
7. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
8. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
9. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
10. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
11. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... CHEYENNE, Wyoming , Feb. 24, 2017  Xynomic ... company, today announced that it has acquired exclusive ... a potentially best-in-class innovative HDAC inhibitor targeting hematological ... total of 14 Phase 1 and 2 clinical ... Asia have already been completed, ...
(Date:2/23/2017)... LG Innotek hat heute die weltweit erste ... das 1,5-fache des 45-mW-Moduls der Konkurrenz. UV-C ... und 280 nm und eignet sich damit für Sterilisationsaufgaben. Es ... zerstört. Das Produkt von LG Innotek erzeugt UV-Strahlung im ... ...
(Date:2/23/2017)... Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die Guian ... Provinz Guizhou, 2017 mit dem Angebot von Anreize schaffenden Strategien ... einer eingebetteten Hightech-Schlüsselindustrie. Foto - http://mma.prnewswire.com/media/471342/First_CRH__CHina_Railway_High_Speed__Train_Enters_Guian.jpg ... ... ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders ... Beyond What You See” body image mannequin art competition. Selected from 15 submissions from ... the winner revealed at the 31st annual iaedp Symposium, March 22 – 26 in ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, the celebrated ... Giveaway, with the winning couple announced on Feb. 14, 2017, on Facebook. The ... local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A Touch of Spring ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which is ... in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) ... website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients and ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information ... National Institute for Health and Care Excellence (NICE) framework. The agreement ... Health Service (NHS) to search, order and purchase medical and healthcare-related content through ...
(Date:2/23/2017)... ... 23, 2017 , ... Current Meditation , a new ... throughout the U.S. starting this spring. Current Meditation focuses on “meditation for the ... Current Meditation will be the first meditation concept in the U.S. offering franchising ...
Breaking Medicine News(10 mins):